Loading
Vizenpistat is an experimental tablet from Stingray Therapeutics that aims to restore an early immune alarm many tumours switch off. It is in early trials, including one with two immunotherapy antibodies in bowel cancer.
Vizenpistat (SR-8541A) is an oral ENPP1 inhibitor developed by Stingray Therapeutics. It is in a phase 1 dose-escalation study alone and with nivolumab or pembrolizumab in advanced solid tumours (NCT06063681) and in a phase 2 study with botensilimab and balstilimab in refractory metastatic microsatellite stable colorectal cancer (NCT06589440). Stingray's website reports eight dose levels cleared without dose-limiting toxicity in the single-agent study; no efficacy results have been published.
Blocks ENPP1, the enzyme that degrades 2'3'-cGAMP, so that cGAMP can activate STING and restore innate immune signalling in the tumour, as the developer describes it.
1.Vizenpistat slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Vizenpistat" OR ABSTRACT:"Vizenpistat" OR TITLE:"SR-8541A" OR ABSTRACT:"SR-8541A" OR TITLE:"SR8541A" OR ABSTRACT:"SR8541A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vizenpistat, not a curated reading list.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/